FORMA Therapeutics, Inc. Teams with TGen Drug Development Services (TD2)

WATERTOWN, Mass. & SCOTTSDALE, Ariz.--(BUSINESS WIRE)--FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

MORE ON THIS TOPIC